Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut check: do probiotics or postbiotics help during antibiotics?

NCT ID NCT07594860

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a probiotic (live bacteria) or a postbiotic (heat-inactivated bacteria) can keep the gut microbiome healthy while people take antibiotics. About 126 healthy adults will receive one of these supplements or a placebo daily for 28 days. Researchers will measure changes in gut bacteria diversity to see if either supplement helps maintain balance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
probiotic (live bacteria) and postbiotic (heat-inactivated bacteria)
What this could lead to
If it works, this could point toward a simple supplement to protect gut health during antibiotic use.
What could go wrong
This is a small, early pilot study in healthy adults, so results may not apply to sick people or lead to a proven product. The supplements may show no benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants meeting ALL of the following criteria will be recruited for the study: * Males and females aged ≥18 to ≤ 65 years; if female, either not of childbearing potential or using a medically approved method of birth control and willing to take a pregnancy test at screening. * Body mass index (BMI) 18.5-29.9 kg/m². * Healthy as determined by medical history and physical examination. * Agreed not to change current dietary habits during the course of the study. * Able to attend study visits, comply with study requirements (consumption of study medications, especially biological sample collection procedures, and study visit schedule) and provide reliable and complete data regarding AEs/SAEs and PROs. * Have been informed and have given written consent for the use of their data in accordance with local regulations before study inclusion. Exclusion Criteria: Participants meeting ANY of the following criteria will be excluded from the study: * Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the study. * People on vegetarian or vegan diet; People on special diet (e.g. Ducan, Keto, etc.) * BMI ≥ 30 kg/m² or \<18.5 kg/m². * History of intake of antibiotics, other probiotics, postbiotics, prebiotics, synbiotics, proton pump inhibitors, acid sequestrants (cholestyramine, Bile colestipol), within six months prior to the screening day. * Participation in other clinical trials in the last 90 days prior to screening. * Allergy to any penicillin antibiotic or any other beta-lactam agent (e.g. cephalosporin, carbapenem or monobactam). * History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid. * Active smokers or using any form of smokeless tobacco. * Participants with substance abuse problems (within two years) defined as: * Use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/ Nicotine dependence. * High-risk drinking as defined by the consumption of four or more alcohol-containing beverages on any day or eight or more alcohol-containing beverages per week for women and five or more alcohol-containing beverages on any day or 15 or more alcohol-containing beverages per week for men. * Participants having clinically significant illnesses of cardiovascular, endocrine, immune, respiratory, hepato-biliary, kidney and urinary, haematological, musculoskeletal system and/or any inflammatory disorder, tumour, and other gastrointestinal diseases. * Participants with a history of bariatric surgery or surgical resection of the stomach, small intestine, or large intestine. * Participants actively using GLP1 agonist drugs (Wegovy, Semiglutide etc.) or completed treatment with said medication less than 12 weeks before screening. * Any condition that could, in the opinion of the Investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Microbiome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dysbiosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital of Thessaloniki Papageorgiou

    Thessaloniki, 56429, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.